One of the leaders in volume daily for penny stocks, Advanced Cell Technology, Inc. (OTC: ACTC), a regenerative medicine working with stem cells, looks forward to conducting Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD) after the Wills Eye Institute in Philadelphia received institutional review board (IRB) approval. SMD is a ...
Global Hunter Securities got it right when the analysts set a “buy” rating and a $5.00 price target on Penny Stock ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC.OB) back on December 1, 2012. IMUC announced the ...
Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of an additional patient in its Phase 1/2 trial for Stargardt’s macular dystrophy using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
The patient was treated on Tuesday (Jan. 24) by Steven Schwartz, M.D., Ahmanson Professor of ...
Continue Reading →